autoimmune disease

Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
Endpoints
Eli Lilly
autoimmune disease
NKTR-358
Nektar
Flag link:
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
Flag link:
Inside the small Norwood biotech that's making investors swoon
Inside the small Norwood biotech that's making investors swoon
Bizjournals.com
Corbus Pharmaceuticals
autoimmune disease
Flag link:
Did Biogen Just Throw in the Towel to Celgene?
Did Biogen Just Throw in the Towel to Celgene?
Motley Fool
Biogen
Celgene
MT-1303
autoimmune disease
ozanimod
Flag link:
Celgene Boldly Targeting $6 Billion (or More) in New Business
Celgene Boldly Targeting $6 Billion (or More) in New Business
Motley Fool
Celgene
Otezla
autoimmune disease
ozanimod
Mongersen
Flag link:
Biogen quietly whisks away its $544M autoimmune rival to Celgene
Biogen quietly whisks away its $544M autoimmune rival to Celgene
Endpoints
Biogen
Celgene
autoimmune disease
amiselimod
ozanimod
Flag link:
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Motley Fool
Celgene
autoimmune disease
Otezla
ozanimod
GED-0301
Flag link:
The Most Exciting Drug in Celgene's Pipeline
The Most Exciting Drug in Celgene's Pipeline
Motley Fool
Celgene
ozanimod
autoimmune disease
Flag link:
Eisai launches research division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases
Eisai launches research division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases
Endpoints
Eisai
R&D
Massachusetts
Alzheimer's disease
autoimmune disease
Flag link:
Allergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million
Allergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million
Marketwatch
Allergan
Vitae
M&A
autoimmune disease
Flag link:
How AbbVie Plans To Replace Humira
How AbbVie Plans To Replace Humira
Seeking Alpha
AbbVie
Humira
R&D
autoimmune disease
ABT-122
ABT-494
ABBV-247
ALX-0061
Flag link:
Can Bristol-Myers Win the Autoimmune Market with Padlock Acquisition?
Can Bristol-Myers Win the Autoimmune Market with Padlock Acquisition?
Bidness, ETC
Bristol-Myers Squibb
Padlock Therapeutics
autoimmune disease
M&A
Flag link:
On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal
On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal
Fierce Biotech
Celgene
Biogen
autoimmune disease
MT-1303
Mitsubishi Tanabe Pharma
Flag link:
AbbVie could end up sidestepping lost sales tied to an expiring patent on Humira in 2017
AbbVie could end up sidestepping lost sales tied to an expiring patent on Humira in 2017
Motley Fool
AbbVie
Humira
patents
Imbruvica
autoimmune disease
Flag link:
Autoimmune Drugs to Drive Big Pharma Higher in Coming Years
Autoimmune Drugs to Drive Big Pharma Higher in Coming Years
24/7 Wall St
autoimmune disease
AbbVie
JNJ
Eli Lilly
Merck
Bristol-Myers Squibb
Pfizer
Flag link:
Astellas wagers $760M to launch an autoimmune biotech in Cambridge, MA
Astellas wagers $760M to launch an autoimmune biotech in Cambridge, MA
Fierce Biotech
Astellas
autoimmune disease
Kanyos Bio
Anokion
Flag link:
Does Celgene Have Another Blockbuster on the Way?
Does Celgene Have Another Blockbuster on the Way?
Investopedia
Celgene
GED-0301
autoimmune disease
Crohn's Disease
Flag link:
Bristol-Myers buys rights to Novo Nordisk immune system project
Bristol-Myers buys rights to Novo Nordisk immune system project
Yahoo/Reuters
Novo Nordisk
Bristol-Myers Squibb
autoimmune disease
Flag link:
Lilly inks a $690M deal to get its hands on an autoimmune drug
Lilly inks a $690M deal to get its hands on an autoimmune drug
Fierce Biotech
Eli Lilly
Korea
Hanmi Pharmaceutical
autoimmune disease
Flag link:
Sanofi beefs up its autoimmune pipeline with a biotech deal
Sanofi beefs up its autoimmune pipeline with a biotech deal
Fierce Biotech
Sanofi
Lead Pharma
autoimmune disease
Flag link: